Achieving the Selectivity Required for the Elusive Trifecta of Safety, Efficacy, & Convenience in IBD Drug Development
Time: 11:00 am
day: Conference Day Two
Details:
- Driving high selectivity of integrin-targeted medicines with Morphic’s MInT Platform
- Leveraging understanding of integrin structure and function to develop novel molecules designed to achieve the potency, high selectivity, and pharmaceutical properties required for oral administration
- Employing innovative end points to accelerate decision making for POC studies in IBD
